Claims
- 1. An immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, comprising:
a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5′-C, G-3′ and wherein said MC is less than 10 μm in size.
- 2. The IMP/MC complex of claim 1, wherein said polynucleotide is covalently linked to said microcarrier.
- 3. The IMP/MC complex of claim 1, wherein said polynucleotide is non-covalently linked to said microcarrier.
- 4. The IMP/MC complex of claim 1, wherein said microcarrier is a liquid phase microcarrier.
- 5. The IMP/MC complex of claim 1, wherein said microcarrier is a solid phase microcarrier.
- 6. The IMP/MC complex of claim 1, wherein said microcarrier is from 25 nm to 5 μm in size.
- 7. The IMP/MC complex of claim 6, wherein said microcarrier is from 1.0 μm to 2.0 μm in size.
- 8. The IMP/MC complex of claim 7, wherein said microcarrier is 1.4 μm in size.
- 9. The IMP/MC complex of claim 7, wherein said microcarrier is cationic.
- 10. The IMP/MC complex of claim 1, wherein said complex is antigen-free.
- 11. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence 5′-T, C, G-3′.
- 12. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence 5′-C, G, pyrimidine, pyrimidine, C, G-3′.
- 13. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′.
- 14. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence SEQ ID NO:1.
- 15. A method of modulating an immune response in an individual comprising administering to an individual an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5′-C, G-3′ and wherein said MC is less than 10 μm in size, in an amount sufficient to modulate an immune response in said individual.
- 16. The method of claim 15, wherein said microcarrier is a solid phase microcarrier.
- 17. The method of claim 15, wherein said microcarrier is a liquid phase microcarrier.
- 18. The method of claim 15, wherein the IMP/MC complex is covalently linked.
- 19. The method of claim 15, wherein the IMP/MC complex is non-covalently linked.
- 20. The method of claim 15, wherein said complex is antigen-free.
- 21. The method of claim 15, wherein a Th1-type immune response is stimulated.
- 22. The method of claim 15, wherein a Th2-type immune response is suppressed.
- 23. The method of claim 15, wherein the ISS comprises the sequence 5′-T, C, G-3′.
- 24. The method of claim 15, wherein the ISS comprises the sequence 5′-C, G, pyrimidine, pyrimidine, C, G-3′.
- 25. The IMP/MC complex of claim 15, wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′.
- 26. The IMP/MC complex of claim 15, wherein the ISS comprises the sequence SEQ ID NO:1.
- 27. A method of increasing interferon-gamma (IFN-γ) in an individual, comprising:
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5′-C, G-3′, wherein said MC is less than 10 μm in size and wherein an effective amount is an amount sufficient to increase IFN-γ in said individual.
- 28. The method of claim 27, wherein said microcarrier is a solid phase microcarrier.
- 29. The method of claim 27, wherein said microcarrier is a liquid phase microcarrier.
- 30. The method of claim 27, wherein the IMP/MC complex is covalently linked.
- 31. The method of claim 27, wherein the IMP/MC complex is non-covalently linked.
- 32. The method of claim 27, wherein said complex is antigen-free.
- 33. The method of claim 27, wherein the ISS comprises the sequence 5′-T, C, G-3′.
- 34. The method of claim 27, wherein the ISS comprises the sequence 5′-C, G, pyrimidine, pyrimidine, C, G-3′.
- 35. The IMP/MC complex of claim 27, wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′.
- 36. The IMP/MC complex of claim 27, wherein the ISS comprises the sequence SEQ ID NO:1.
- 37. A method of increasing interferon-alpha (IFN-α) in an individual, comprising:
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5′-C, G-3′, wherein said MC is less than 10 μm in size and wherein an effective amount is an amount sufficient to increase IFN-α in said individual.
- 38. The method of claim 37, wherein said individual has a viral infection.
- 39. The method of claim 37, wherein said microcarrier is a solid phase microcarrier.
- 40. The method of claim 37, wherein said microcarrier is a liquid phase microcarrier.
- 41. The method of claim 37, wherein the IMP/MC complex is covalently linked.
- 42. The method of claim 37, wherein the IMP/MC complex is non-covalently linked.
- 43. The method of claim 37, wherein said complex is antigen-free.
- 44. The method of claim 37, wherein the ISS comprises the sequence 5′-T, C, G-3′.
- 45. The method of claim 37, wherein the ISS comprises the sequence 5′-C, G, pyrimidine, pyrimidine, C, G-3′.
- 46. The IMP/MC complex of claim 37, wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′.
- 47. The IMP/MC complex of claim 37, wherein the ISS comprises the sequence SEQ ID NO:1.
- 48. A method of reducing levels of IgE in an individual, comprising:
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5′-C, G-3′, wherein said MC is less than 10 μm in size and wherein an effective amount is an amount sufficient to reducing levels of IgE in said individual.
- 49. The method of claim 48, wherein said microcarrier is a solid phase microcarrier.
- 50. The method of claim 48, wherein said microcarrier is a liquid phase microcarrier.
- 51. The method of claim 48, wherein the IMP/MC complex is covalently linked.
- 52. The method of claim 48, wherein the IMP/MC complex is non-covalently linked.
- 53. The method of claim 48, wherein said complex is antigen-free.
- 54. The method of claim 48, wherein the ISS comprises the sequence 5′-T, C, G-3′.
- 55. The method of claim 48, wherein the ISS comprises the sequence 5′-C, G, pyrimidine, pyrimidine, C, G-3′.
- 56. The IMP/MC complex of claim 48, wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′.
- 57. The IMP/MC complex of claim 48, wherein the ISS comprises the sequence SEQ ID NO:1.
- 58. A kit, comprising:
a container comprising an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, wherein the ISS comprises the sequence 5′-C, G-3′, wherein said MC is a biodegradable MC and wherein said MC is less than 10 μm in size; and instructions for use of IMP/MC complex in immunodulation of an individual.
- 59. The kit of claim 58, wherein said polynucleotide is covalently linked to said microcarrier.
- 60. The kit of claim 58, wherein said polynucleotide is non-covalently linked to said microcarrier.
- 61. The kit of claim 58, wherein said microcarrier is a liquid phase microcarrier.
- 62. The kit of claim 58, wherein said microcarrier is a solid phase microcarrier.
- 63. The kit of claim 58, wherein said microcarrier is from 25 nm to 5 μm in size.
- 64. The kit of claim 63, wherein said microcarrier is from 1.0 μm to 2.0 μm in size.
- 65. The kit of claim 64, wherein said microcarrier is 1.4 μm in size.
- 66. The kit of claim 58, wherein said microcarrier is cationic.
- 67. The kit of claim 58, wherein said complex is antigen-free.
- 68. The kit of claim 58, wherein the ISS comprises the sequence 5′-T, C, G-3′.
- 69. The kit of claim 58, wherein the ISS comprises the sequence 5′-C, G, pyrimidine, pyrimidine, C, G-3′.
- 70. The kit of claim 58, wherein the ISS comprises the sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3′.
- 71. The kit of claim 58, wherein the ISS comprises the sequence SEQ ID NO:1.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit of U.S. Provisional application 60/188,303, filed Mar. 10, 2000, which is hereby incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60188303 |
Mar 2000 |
US |